STLN
Starling Oncology Inc.
STLN | NASDAQ
$6.53
-$0.12 (-1.80%)
At close: Oct 30, 2026, 3:59 PM ET
$6.62
+$0.09 (+1.38%)
Pre-market:
Nov 2, 2026, 7:09 AM ET
TTM Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 |
|---|---|---|---|---|
Revenue | 587.24M | 425.96M | 278.52M | 136.56M |
Cost of Revenue | 495.08M | 360.96M | 236.84M | 117.64M |
Gross Profit | 92.17M | 65M | 41.69M | 18.92M |
Operating Income | -26.09M | -21.47M | -14.96M | -8.05M |
Interest Income | n/a | n/a | n/a | n/a |
Pretax Income | -36.29M | -26.5M | -24.01M | -16.5M |
Net Income | -36.29M | -26.5M | -24.01M | -16.5M |
Selling & General & Admin | 111.45M | 81.5M | 53.29M | 25.25M |
Research & Development | n/a | n/a | n/a | n/a |
Other Expenses | 6.81M | 4.97M | 3.36M | 1.72M |
Operating Expenses | 118.26M | 86.47M | 56.65M | 26.97M |
Interest Expense | 7.63M | 5.77M | 3.84M | 1.92M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a |
Cost & Expenses | 613.33M | 447.44M | 293.48M | 144.62M |
Income Tax Expense | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 103.03M | 101.8M | 101.46M | 97.47M |
Shares Outstanding (Diluted) | 103.03M | 101.8M | 101.46M | 97.47M |
EPS (Basic) | -0.30 | -0.22 | -0.20 | -0.14 |
EPS (Diluted) | -0.30 | -0.22 | -0.20 | -0.14 |
EBITDA | -21.86M | -15.76M | -16.82M | -12.86M |
EBIT | -28.66M | -20.73M | -20.18M | -14.58M |
Depreciation & Amortization | 6.81M | 4.97M | 3.36M | 1.72M |
Add to Watchlist
Select watchlists to add or remove STLN